Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Why did the Senate block restraining Trump on Iran strikes? How will Trump’s trade talks end affect US-Canada relations? What drove Nvidia’s recent stock rally to record highs? Why is Warren Buffett donating billions in Berkshire shares? How are AI developments impacting Wall Street trading? Why did Nike stock soar despite tariff-related challenges? What changes will the Supreme Court ruling on injunctions bring?

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

finance.yahoo.com/news/edgewise-therapeutics-price-target-lowered-132514884.html

In This Article:
Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker…

This story appeared on finance.yahoo.com, 2025-06-28 13:25:14.